Eleanor Peters, MD
Family Medicine · Danville, ILNPI 1942217542
Payments from drug & device makers
Across 266 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$482
- AstraZeneca$453
- Novo Nordisk$453
- Novartis$341
- Boehringer Ingelheim$278
- Lilly USA, LLC$235
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,96899%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 39 | $482 |
| AstraZeneca | 23 | $453 |
| Novo Nordisk | 36 | $453 |
| Novartis | 20 | $341 |
| Boehringer Ingelheim | 17 | $278 |
| Lilly USA, LLC | 15 | $235 |
| Amgen | 15 | $222 |
| Pfizer | 22 | $201 |
| AbbVie(2 entities) | 7 | $154 |
| Johnson & Johnson | 8 | $135 |
| Daiichi Sankyo Inc. | 6 | $122 |
| Astellas Pharma US Inc | 6 | $101 |
| Otsuka America Pharmaceutical, Inc. | 5 | $82 |
| Bayer | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $69 |
| Ironshore Pharmaceuticals Inc. | 4 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Dexcom, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Corcept Therapeutics | 4 | $48 |
| Abbott | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Phadia US Inc. | 1 | $13 |
How this compares
$4,012 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 146 | $160,427 |
| EliquisApixaban | 109 | $130,995 |
| JardianceEmpagliflozin | 101 | $122,613 |
| JanuviaSitagliptin Phosphate | 43 | $47,526 |
| XareltoRivaroxaban | 38 | $46,314 |
| RybelsusSemaglutide | 26 | $40,486 |
| TrulicityDulaglutide | 24 | $35,894 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $26,153 |
| FarxigaDapagliflozin Propanediol | 24 | $24,221 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,764 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $14,935 |
| TradjentaLinagliptin | 14 | $14,563 |
| MounjaroTirzepatide | 13 | $14,174 |
| VascepaIcosapent Ethyl | 24 | $12,545 |
| LinzessLinaclotide | 15 | $12,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $453 | $200,913172 claims |
| Boehringer IngelheimJardiance, Tradjenta | $278 | $137,176115 claims |
| PfizerEliquis | $201 | $130,995109 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $482 | $59,298107 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $235 | $50,06837 claims |
| Johnson & JohnsonXarelto | $135 | $46,31438 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $453 | $39,96263 claims |
| AbbVieLinzess | $154 | $12,12515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Danville
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.